Notch signaling in pancreatic cancer: Oncogene or tumor suppressor?

Trends in Molecular Medicine

Volumn 19, Issue 5, 2013, Pages 320-327

  Avila, Jacqueline L ^a   Kissil, Joseph L ^b  

^a WISTAR INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Gamma secretase inhibitor; Kras; Notch; Pancreatic ductal adenocarcinoma; PanIN

Indexed keywords

NOTCH RECEPTOR;

CARCINOGENESIS; DRUG TARGETING; HUMAN; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84877149088     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.03.003     Document Type: Review

References (68)

1. Ottenhof N.A., et al. Molecular characteristics of pancreatic ductal adenocarcinoma. Pathol. Res. Int. 2011, 2011:620601.
2. Maitra A., Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
3. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2002, 2:897-909.
4. Almoguera C., et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
5. Vakiani E., Solit D.B. KRAS and BRAF: drug targets and predictive biomarkers. J. Pathol. 2011, 223:219-229.
6. Weijzen S., et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002, 8:979-986.
7. Kiaris H., et al. Modulation of Notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am. J. Pathol. 2004, 165:695-705.
8. Miyamoto Y., et al. Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
9. Hingorani S.R., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
10. Brembeck F.H., et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 2003, 63:2005-2009.
11. Kopp J.L., et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:737-750.
12. Carriere C., et al. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4437-4442.
13. Guerra C., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
14. Habbe N., et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18913-18918.
15. Tosh D., Slack J.M. How cells change their phenotype. Nat. Rev. Mol. Cell Biol. 2002, 3:187-194.
16. Means A.L., et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 2005, 132:3767-3776.
17. Scotti M.L., et al. Protein kinase C iota regulates pancreatic acinar-to-ductal metaplasia. PLoS ONE 2012, 7:e30509.
18. Avila J.L., et al. Notch1 is not required for acinar-to-ductal metaplasia in a model of Kras-induced pancreatic ductal adenocarcinoma. PLoS ONE 2012, 7:e52133.
19. Strobel O., et al. In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 2007, 133:1999-2009.
20. Stanger B.Z., et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8:185-195.
21. Parsa I., et al. Ductal metaplasia of human exocrine pancreas and its association with carcinoma. Cancer Res. 1985, 45:1285-1290.
22. Aichler M., et al. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J. Pathol. 2012, 226:723-734.
23. Gidekel Friedlander S.Y., et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009, 16:379-389.
24. Morris J.P.T., et al. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 2010, 10:683-695.
25. Jensen J.N., et al. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology 2005, 128:728-741.
26. Morris J.P.T., et al. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 2010, 120:508-520.
27. Apelqvist A., et al. Notch signalling controls pancreatic cell differentiation. Nature 1999, 400:877-881.
28. Jensen J., et al. Control of endodermal endocrine development by Hes-1. Nat. Genet. 2000, 24:36-44.
29. Murtaugh L.C., et al. Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14920-14925.
30. Nakhai H., et al. Conditional ablation of Notch signaling in pancreatic development. Development 2008, 135:2757-2765.
31. Golson M.L., et al. Ductal malformation and pancreatitis in mice caused by conditional Jag1 deletion. Gastroenterology 2009, 136:1761-1771.
32. Siveke J.T., et al. Notch signaling is required for exocrine regeneration after acute pancreatitis. Gastroenterology 2008, 134:544-555.
33. Hanlon L., et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010, 70:4280-4286.
34. Esni F., et al. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development 2004, 131:4213-4224.
35. Shih H.P., et al. A Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell differentiation. Development 2012, 139:2488-2499.
36. Kopinke D., et al. Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreas. Dev. Biol. 2012, 362:57-64.
37. Mazur P.K., et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13438-13443.
38. Plentz R., et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136:1741-1749.
39. Ranganathan P., et al. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11:338-351.
40. Lobry C., et al. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 2011, 208:1931-1935.
41. Donnem T., et al. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 2010, 116:5676-5685.
42. Reedijk M., et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65:8530-8537.
43. Sjolund J., et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J. Clin. Invest. 2008, 118:217-228.
44. Santagata S., et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004, 64:6854-6857.
45. Pece S., et al. NUMB-ing down cancer by more than just a NOTCH. Biochim. Biophys. Acta 2011, 1815:26-43.
46. Maraver A., et al. Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 2012, 22:222-234.
47. van Es J.H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
48. Groth C., et al. Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP. Mol. Pharmacol. 2010, 77:567-574.
49. Wu Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.
50. Groth C., Fortini M.E. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin. Cell Dev. Biol. 2012, 23:465-472.
51. Nicolas M., et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003, 33:416-421.
52. Demehri S., et al. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009, 16:55-66.
53. Thelu J., et al. Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol. 2002, 2:7.
54. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat. Rev. Drug Discov. 2010, 9:749-751.
55. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell. Mol. Life Sci. 2007, 64:2746-2762.
56. Klinakis A., et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473:230-233.
57. Agrawal N., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
58. Wang N.J., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17761-17766.
59. Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
60. De La O.J., et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18907-18912.
61. Mazzone M., et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5012-5017.
62. Cook N., et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med. 2012, 209:437-444.
63. Sawey E.T., et al. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19327-19332.
64. Ardito C.M., et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
65. Rooman I., et al. Expression of the Notch signaling pathway and effect on exocrine cell proliferation in adult rat pancreas. Am. J. Pathol. 2006, 169:1206-1214.
66. Yuan Z., et al. Characterization of CSL (CBF-1, Su(H), Lag-1) mutants reveals differences in signaling mediated by Notch1 and Notch2. J. Biol. Chem. 2012, 287:34904-34916.
67. Hashimoto T., et al. VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 2006, 133:2201-2210.
68. Sundaram M.V. The love-hate relationship between Ras and Notch. Genes Dev. 2005, 19:1825-1839.